HGH Stock Overview
Provides various financial services in New Zealand and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Heartland Group Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$0.89 |
| 52 Week High | NZ$1.55 |
| 52 Week Low | NZ$0.86 |
| Beta | 1.01 |
| 11 Month Change | -4.84% |
| 3 Month Change | -13.66% |
| 1 Year Change | -42.16% |
| 33 Year Change | -59.77% |
| 5 Year Change | n/a |
| Change since IPO | -39.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| HGH | AU Banks | AU Market | |
|---|---|---|---|
| 7D | -1.1% | 3.6% | 1.5% |
| 1Y | -42.2% | 45.9% | 17.2% |
Return vs Industry: HGH underperformed the Australian Banks industry which returned 45.9% over the past year.
Return vs Market: HGH underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| HGH volatility | |
|---|---|
| HGH Average Weekly Movement | 5.1% |
| Banks Industry Average Movement | 3.6% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: HGH has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: HGH's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1875 | n/a | Andrew Dixson | www.heartlandgroup.info |
Heartland Group Holdings Limited, together with its subsidiaries, provides various financial services in New Zealand and Australia. It operates through Motor, Reverse Mortgages, Personal Lending, Business, Rural, and Australian Banking Group segments. The company offers motor vehicle finance; reverse mortgage lending; and transactional, home loans, and personal loans to individuals.
Heartland Group Holdings Limited Fundamentals Summary
| HGH fundamental statistics | |
|---|---|
| Market cap | AU$835.56m |
| Earnings (TTM) | AU$67.12m |
| Revenue (TTM) | AU$219.62m |
12.4x
P/E Ratio0.7x
P/B RatioIs HGH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HGH income statement (TTM) | |
|---|---|
| Revenue | NZ$243.93m |
| Cost of Revenue | NZ$0 |
| Gross Profit | NZ$243.93m |
| Other Expenses | NZ$169.38m |
| Earnings | NZ$74.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.08 |
| Gross Margin | 100.00% |
| Net Profit Margin | 30.56% |
| Debt/Equity Ratio | 165.6% |
How did HGH perform over the long term?
See historical performance and comparison